Ascendis Pharma Endocrinology Division A/S

Clinical trials sponsored by Ascendis Pharma Endocrinology Division A/S, explained in plain language.

Ascendis Pharma Endocrinology Division A/S ASND NASDAQ

A biopharmaceutical company focused on endocrinology treatments.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 2 Not yet finished but already full! 1 Completed 4

Weekly shot may replace daily growth hormone for turner syndrome kids

Disease control Ongoing

This study tests a new long-acting growth hormone (lonapegsomatropin) given once a week, compared to the standard daily growth hormone shot, in 48 prepubertal children with Turner syndrome who have not had growth hormone before. The goal is to see if the weekly shot is safe and h…

Phase 2 • Sponsor: Ascendis Pharma Endocrinology Division A/S • Aim: Disease control

Last updated Jun 27, 2026 12:33 UTC

Ascendis Pharma Endocrinology Division A/S

Weekly shot may replace daily growth hormone for turner syndrome kids